$11.6M, 25,000 Waitlist Orders, One Wearable that Claims to Read Your Hormones

No blood draw. No urine test. Just a wristband — and a very large question about what it can actually prove.

Clair Health raised $11.6 million in seed funding to build what it's calling the first noninvasive continuous hormone monitor for women — a wristband that tracks estrogen, progesterone, LH, and FSH in real time without blood draws or urine tests. Khosla Ventures led the round, with participation from a16z speedrun, Brydge Club, and 23andMe co-founder Anne Wojcicki. The device ships November 2026 and has 25,000 people on its waitlist. The absence of peer-reviewed clinical validation is the more instructive data point — and not because it stopped the raise. Khosla and a16z speedrun bet on technical architecture and team before evidence exists; that's seed stage. The relevant signals were a 25,000-person waitlist, no incumbent built from the ground up for hormone monitoring, and Anne Wojcicki — who knows this data problem from 23andMe — writing a check. The harder question arrives in November, when Clair ships. FDA clearance, employer benefit evaluation, and clinical utility all require published accuracy data. The waitlist proves demand. It doesn't prove the device works. Plus: Spain triples women's health research funding to €18 million, June Health closes C$2.4 million for employer-sponsored femtech in Canada, and Oncoinvent hits its 50% recruitment milestone in a Phase 2 ovarian cancer trial. Five takes inside, plus quick hits.